quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 26, 2026

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness

View original at finance.yahoo.com
Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Sanofi currently has a value score of 6 out of 6

    60% confidence

  • There are 230 or more high quality undervalued stocks available to discover on Simply Wall St's platform

    60% confidence

  • Simply Wall St is trusted by over 7 million individual investors worldwide

    60% confidence

  • Sanofi's -9.5% return over the last year is lagging behind its pharmaceutical sector peers

    60% confidence

  • Recent sentiment around Sanofi has been mixed due to broader pharmaceutical sector dynamics, regulatory developments, and shifting investor attention within healthcare

    60% confidence

  • Sanofi is undervalued by 68.7% according to a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of €255.70 per share versus a current price of approximately €80.08

    60% confidence

  • Analyst and extrapolated forecasts project Sanofi's free cash flow to reach €12.72 billion in 2030, with intermediate annual projections through 2035

    60% confidence

Data points we hold from this source

Sanofi · margin-68.7 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness — Source | Via News | pt.VIA.NEWS